Issue Of Shares & Pdmr Announcement
September 20 2018 - 11:49AM
UK Regulatory
TIDMVRP
LONDON, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, announces that it today issued 251,125 new
Ordinary Shares (the "New Ordinary Shares") following the vesting of
restricted stock units held by employees in the Company. Application
will be made to the London Stock Exchange for the New Ordinary Shares to
be admitted to trading on AIM, with dealings expected to commence on 25
September 2018 ("Admission"). Following Admission, the Company will have
a total of 105,326,638 Ordinary Shares in issue each carrying one voting
right. The Company does not hold any Ordinary Shares in Treasury. This
figure of 105,326,638 Ordinary Shares may be used by shareholders as the
denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their interest
in, the share capital of the Company under the FCA's Disclosure and
Transparency Rules.
Following the issue, Dr. Jan-Anders Karlsson, CEO of Verona Pharma, will
have an interest in the Company of 193,545 Ordinary Shares, representing
0.18% of the Company's issued share capital, and Mr. Piers Morgan, CFO
of the Company, will have an interest in the Company of 58,594 Ordinary
Shares, representing 0.06% of the Company's issued share capital.
The notification set out below is provided in accordance with the
requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person
closely associated
--- -------------------------------------------------------------------------------------------------------------------
a) Name Jan-Anders Karlsson
--- ----------------------------------------------------------- ------------------------------------------------------
2 Reason for the notification
--- -------------------------------------------------------------------------------------------------------------------
Director
a) Position/status
--- ----------------------------------------------------------- ------------------------------------------------------
b) Initial notification/Amendment Initial notification
--- ----------------------------------------------------------- ------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- -------------------------------------------------------------------------------------------------------------------
a) Name Verona Pharma plc
--- ----------------------------------------------------------- ------------------------------------------------------
b) LEI 213800EVI6O6J3TIAL06
--- ----------------------------------------------------------- ------------------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--- -------------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument Ordinary Shares of 5 pence each
Identification code GB00BYW2KH80
--- ----------------------------------------------------------- ------------------------------------------------------
b) Nature of the transaction Jan-Anders Karlsson was issued 101,145 Ordinary Shares
following the vesting of restricted stock units under
the Company's employee share plan
--- ----------------------------------------------------------- ------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
N/A 101,145 Ordinary Shares
--- ----------------------------------------------------------- ------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
--- ----------------------------------------------------------- ------------------------------------------------------
e) Date of the transaction 20 September 2018
--- ----------------------------------------------------------- ------------------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
--- ----------------------------------------------------------- ------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
--- -----------------------------------------------------------------------------------------------------------------------
a) Name Piers Morgan
--- ----------------------------------------------------------- ----------------------------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------------------------------------------------------------------
Chief Financial Officer
a) Position/status
--- ----------------------------------------------------------- ----------------------------------------------------------
b) Initial notification/Amendment Initial notification
--- ----------------------------------------------------------- ----------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- -----------------------------------------------------------------------------------------------------------------------
a) Name Verona Pharma plc
--- ----------------------------------------------------------- ----------------------------------------------------------
b) LEI 213800EVI6O6J3TIAL06
--- ----------------------------------------------------------- ----------------------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--- -----------------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument Ordinary Shares of 5 pence each
Identification code GB00BYW2KH80
--- ----------------------------------------------------------- ----------------------------------------------------------
b) Nature of the transaction Piers Morgan was issued 58,594 Ordinary Shares following
the vesting of restricted stock units under the Company's
employee share plan
--- ----------------------------------------------------------- ----------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
N/A 58,594 Ordinary Shares
--- ----------------------------------------------------------- ----------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
--- ----------------------------------------------------------- ----------------------------------------------------------
e) Date of the transaction 20 September 2018
--- ----------------------------------------------------------- ----------------------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
--- ----------------------------------------------------------- ----------------------------------------------------------
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20 7710 7600
and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison
(END) Dow Jones Newswires
September 20, 2018 11:49 ET (15:49 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024
